New Faces Top Tables In ‘Top Partners’ Survey Amidst Overall Decline
Celgene and Novo Nordisk crash what is typically a Big Pharma party with high marks in BCG’s latest biopharmaceutical partnering survey. But overall impressions of industry’s partnering prowess are down across the board.
You may also be interested in...
The December US launch of linaclotide is a transformative event for Ironwood Pharmaceuticals, the GI drug’s discoverer. But the company’s recent deal with AstraZeneca to sell the drug in China represents another kind of feat and highlights the growing importance of regional deals to Western biotechs.
Epizyme’s recent alliance with Celgene validates industry’s interest in histone methyltransferase inhibitors, a kinase-like class of epigenetic enzymes. Celgene’s willingness to cede US rights in return for access to preclinical assets belies HMTs’ novelty and helps to position Epizyme for potential success as a US-focused oncology company. Despite the strong start, it won’t be easy.
US regulators are proposing updates to a guidance document they finalized in February for devices used to clear arteries of plaque. The updated language specifically addresses software interoperability, pyrogenicity and certain performance-testing requirements.